Representative Jefferson Shreve (R-Indiana) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Gilead Sciences stock on March 31st. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025.
- Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025.
- Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025.
- Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025.
- Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025.
- Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025.
Gilead Sciences Stock Down 0.4 %
Shares of GILD traded down $0.39 during trading hours on Friday, hitting $104.49. The company had a trading volume of 8,066,368 shares, compared to its average volume of 7,519,796. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a fifty day moving average price of $109.16 and a 200-day moving average price of $97.45. The stock has a market capitalization of $130.10 billion, a price-to-earnings ratio of 282.40, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio is currently 854.05%.
Insider Activity
In other news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on GILD shares. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. BMO Capital Markets increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Morgan Stanley upped their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Finally, DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $105.12.
View Our Latest Analysis on Gilead Sciences
Institutional Investors Weigh In On Gilead Sciences
Several large investors have recently bought and sold shares of GILD. Clarius Group LLC grew its stake in shares of Gilead Sciences by 21.3% in the 1st quarter. Clarius Group LLC now owns 8,308 shares of the biopharmaceutical company's stock worth $931,000 after buying an additional 1,460 shares in the last quarter. Rakuten Securities Inc. raised its position in Gilead Sciences by 2,645.8% during the first quarter. Rakuten Securities Inc. now owns 659 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 635 shares during the period. Wagner Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 2.5% in the 1st quarter. Wagner Wealth Management LLC now owns 8,927 shares of the biopharmaceutical company's stock worth $1,000,000 after purchasing an additional 217 shares during the period. Berkshire Bank boosted its stake in Gilead Sciences by 11.2% during the first quarter. Berkshire Bank now owns 3,777 shares of the biopharmaceutical company's stock worth $423,000 after buying an additional 379 shares during the period. Finally, Vista Investment Partners LLC bought a new position in Gilead Sciences during the first quarter valued at $237,000. Institutional investors own 83.67% of the company's stock.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
